Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Multiple Dose Study of CNT-01
jRCT2071210012Phase 1Completed
- Sponsor
- TOA EIYO
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tricaprin in idiopathic triglyceride deposit cardiomyovasculopathy (I-TGCV) (4 arms), sponsored by TOA EIYO. Primary endpoints: Pharmacokinetics of CNT-01, Effect on QTcF and 1 more. Started Apr 2021; status: completed.
02
Drugs
tricaprin
03
Conditions
idiopathic triglyceride deposit cardiomyovasculopathy (I-TGCV)
Beyond the preview
Go deeper on jRCT2071210012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210012.